DNA Damage Repair: Predictor of Platinum Efficacy in Ovarian Cancer?
Ovarian cancer (OC) is the seventh most common type of cancer in women worldwide. Treatment for OC usually involves a combination of surgery and chemotherapy with carboplatin and paclitaxel. Platinum-based agents exert their cytotoxic action through development of DNA damage, including the formation...
Main Authors: | Dimitra T. Stefanou, Vassilis L. Souliotis, Roubini Zakopoulou, Michalis Liontos, Aristotelis Bamias |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-12-01
|
Series: | Biomedicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9059/10/1/82 |
Similar Items
-
Platinum-Resistant Ovarian Cancer Is Vulnerable to the cJUN-XRCC4 Pathway Inhibition
by: Manman Xu, et al.
Published: (2022-12-01) -
Ovarian Cancer—Insights into Platinum Resistance and Overcoming It
by: Andrei Havasi, et al.
Published: (2023-03-01) -
The Poor Prognosis of Acquired Secondary Platinum Resistance in Ovarian Cancer Patients
by: Osnat Elyashiv, et al.
Published: (2024-02-01) -
Clinicopathological and Functional Evaluation Reveal NBS1 as a Predictor of Platinum Resistance in Epithelial Ovarian Cancers
by: Adel Alblihy, et al.
Published: (2021-01-01) -
The function of TTK1 in platinum-resistant ovarian cancer
by: LIU Yixuan , WEN Zexuan , GUO Lin , LU Renquan
Published: (2021-03-01)